Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Replimune Group, Inc. (REPL : NSDQ)

• Company Description    Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. Number of Employees: 479

• Price / Volume Information    Yesterday's Closing Price: $8.31 Daily Weekly Monthly 20 Day Moving Average: 8,744,022 shares Shares Outstanding: 78.44 (millions) Market Capitalization: $651.86 (millions) Beta: 0.79 52 Week High: $17.00 52 Week Low: $2.68 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 83.44% 78.64% 12 Week 49.46% 43.26% Year To Date -31.38% -40.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 Unicorn Park Drive Suite 303 - WOBURN,MA 01801 USA ph: 781-222-9600 fax: - ir@replimune.com http://www.replimune.com

• General Corporate Information    Officers Sushil Patel - Chief Executive Officer and Director Emily Hill - Chief Financial Officer Andrew Schwendenman - Chief Accounting Officer Philip Astley-Sparke - Director Kapil Dhingra - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76029N106 SIC: 2836 Fiscal Year Fiscal Year End: March Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/11/26 Share - Related Items Shares Outstanding: 78.44 Most Recent Split Date: (:1) Beta: 0.79 Market Capitalization: $651.86 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.79 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.92 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -32.35% vs. Previous Quarter: 5.26% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -75.37 06/30/25 - -69.34 03/31/25 - -57.98 ROA 09/30/25 - -57.30 06/30/25 - -52.81 03/31/25 - -45.21 Current Ratio 09/30/25 - - 06/30/25 - 6.94 03/31/25 - 7.95 Quick Ratio 09/30/25 - - 06/30/25 - 6.94 03/31/25 - 7.95 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 4.33 03/31/25 - 5.40 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.21 03/31/25 - 0.17 Debt-to-Capital 09/30/25 - - 06/30/25 - 17.08 03/31/25 - 14.25

Powered by Zacks Investment Research ©